Research Article

Hot Melt Extruded Amorphous Solid Dispersion of Posaconazole with Improved Bioavailability: Investigating Drug-Polymer Miscibility with Advanced Characterisation

Ritesh Fule and Purnima Amin
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Nathalal Parekh Marg, Matunga, Mumbai, Maharashtra 400019, India

Correspondence should be addressed to Ritesh Fule; riteshpbd.ict@gmail.com

Received 13 February 2014; Revised 31 March 2014; Accepted 2 April 2014; Published 21 July 2014

Academic Editor: Frederic Lagarce

Copyright © 2014 R.Fule and P.Amin. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Invasive antifungal infections are reasons for morbidity and mortality in immunogenic patients worldwide. Posaconazole is a most promising antifungal agent against all types of invasive infections with high % of cure rate. The marketed suspension formulation has low bioavailability and is needed to be taken with food. In this paper, PCZ hot melt extruded amorphous solid dispersion (SD) with immediate release and improved bioavailability was prepared using Soluplus (Sol) as primary carrier for solubilization. Surfactants such as PEG 400, Lutrol F27, Lutrol F68, and TPGS are also used in combination with Soluplus to improve the physicochemical performance of the formulation when it comes in contact with GI (gastrointestinal) fluid. Drug-polymer miscibility of SD was investigated using advanced techniques. In the in vivo study, the AUC_{0-72} and C_{max} of PCZ/Soluplus were 11.5 and 11.74 time higher than those of pure PCZ. The formulation of the extrudate SD had an AUC_{0-72} and C_{max} higher than those with the commercial capsule (Noxafil). Molecular dynamic (MD) simulation studies were carried out using in silico molecular modelling to understand the drug-polymer intermolecular behaviour. The results of this research ensure enhanced dissolution and bioavailability of the solid dispersion of PCZ prepared by HME compared with the PCZ suspension.

1. Introduction

The solubility and dissolution rate of drugs relics one of the most challenging traits in formulation development. Hot melt extrusion (HME) has been established as novel strategy to produce delivery system with enhanced bioavailability as well as solubility of dissolution rate limited APIs in pharmaceutical drug development research [1–3]. This technology employs the combination of optimized parameter and temperature to formulate drug-polymer molecularly dispersed systems, which can be termed as solid dispersion (SD) or solid solution [4, 5]. The singularity and workability of the procedural features allow the development of several drug delivery systems. Also, various marketed formulations are available prepared via HME [6]. The formation of melt extrusion involves the exchange of heat energy during HME process and followed by instant cooling of the melt which affects thermodynamic and kinetic properties of forming SD apparently [7, 8]. Use of highly water soluble carrier in SD always increases the chances of crystallization due to swelling behavior when it comes in contact with the aqueous GI fluid [9]. Therefore, surfactant agents or surfactants are used as inhibitors for recrystallization. HME has the unique property to maintain the amorphous state of the drug after the formation of SD and improves the solubility of the drug. Solubility of the drug substance has a significant impact on its bioavailability performance. The literature cited various methods for preparing amorphous SD such as melt method, solvent evaporation, cyclodextrin inclusion complex, and cryomilling which explained the importance of SD type of formulation strategy [10].

Posaconazole (PCZ) is newly developed extended-spectrum triazole with proven efficacy as antifungal treatment
and used to treat invasive infections by *candida* species and *aspergillus* species in severely immunogenic patients. The marketed oral suspension Noxafil (40 mg/mL of PCZ concentration) should be taken with food to maximize systemic absorption. In this paper a new solid oral SD formulation has been developed using HME with improved bioavailability that can be administered without regard to food. PCZ has a very low aqueous solubility which impairs its dissolution in upper gastric fluid producing problems to prepared systems [11]. Overall, these characteristics hinder its therapeutic application by delaying the absorption rate and thereby onset of action or activity [12]. Together solubility, permeability, and dissolution rates of a drug are essential factors for determining its oral bioavailability. The literature reports generally revealed the fact that drug materials with a very low aqueous solubility will show dissolution rate limited absorption and hence poor bioavailability. Improvement of aqueous solubility in such a case is a valuable assignment to improve therapeutic efficacy [13]. PCZ is structurally analogous to itraconazole. Itraconazole has been extensively studied by various researchers comprising its SD formulating method reported. Subsequently there is a need to deliver itraconazole analogues to disordered sticky heterogeneous extrudes. But with addition of selected surfactant the torque decreases and molar attraction constant due to molar dispersion forces, \( \delta_h \) is the contribution from hydrogen bonding, \( F_{g1} \) is the molar attraction constant due to molar dispersion forces, \( F_{g2} \) is the molar attraction constant due to molar polarization forces, \( h_2 \) is the hydrogen bonding energy, and \( K \) is the molar volume. The solubility parameters of polymer and surfactant combinations were calculated using the following equation:

\[
\delta^2 = \delta^2_d + \delta^2_p + \delta^2_h,  
\]

where

\[
\delta_d = \frac{\sum F_{g1}}{V}, \quad \delta_p = \left( \frac{\sum F_{g2}}{V} \right)^{1/2}, \quad \delta_h = \left( \frac{\sum F_{h2}}{V} \right)^{1/2}. 
\]

Here \( i \) is the groups within the molecule, \( \delta \) is the total solubility parameter, \( \delta_p \) is the contribution from dispersion forces, \( \delta_h \) is the contribution from polar interactions, \( \delta_p \) is the contribution of hydrogen bonding, \( F_{g1} \) is the molar attraction constant due to molar dispersion forces, \( F_{g2} \) is the molar attraction constant due to molar polarization forces, \( h_2 \) is the hydrogen bonding energy, and \( V \) is the molar volume. The solubility parameters of polymer and surfactant combinations were calculated using the following equation:

\[
\delta_{1,2} = V' \delta_1 + V'' \delta_2, 
\]

where \( V' \) is the volume fraction of each compound.

Miscibility of the drug with the polymer can be assessed based on the shift in melting endotherm or \( T_{g1} \) of the drug or can be predicted theoretically using Gordon-Taylor equation based on the \( T_{g1} \) densities, and weight fractions of the components. Consider

\[
T_{g \text{mix}}(\text{HME system}) = W_1 T_{g1} + K W_2 T_{g2} + K W_2 W_1, 
\]

\[
K = \frac{T_{g1}P_1}{T_{g2}P_2}, 
\]

where \( T_{g1} \) is the glass transition temperature of drug, \( W_1 \) and \( W_2 \) are the weight fractions of the components, and \( K \) is the parameter calculated from the true densities (\( \rho_1 \) of drug and \( \rho_2 \) of polymer) and \( T_{g2} \) of the amorphous components [16]. The true density measurement of the PCZ and polymers was determined in duplicate using a gas displacement pycnometer (Accupyc 1330; Micromeritics, Norcross, Georgia).

The Flory-Huggins (FH) interaction parameter (\( \chi \)) was calculated using the following equation:

\[
\frac{1}{T_{m \text{mix}}} - \frac{1}{T_{m \text{pure}}} = - \frac{R}{\Delta H_f} \left\{ \ln \Phi_{\text{drug}} + \left( 1 - \frac{1}{m} \right) \Phi_{\text{polymer}} + \chi \Phi_{\text{polymer}}^2 \right\}, 
\]

2. Materials and Methods

2.1. Materials. PCZ was obtained as a generous gift from ABS life science Ltd., India. Sol, LF127, LF68, and TPGs were kindly donated by BASF Corporation, Mumbai, India (head office Ludwigshafen, Germany). PEG400 of analytical grade was procured from Sd. Fine Chemicals, Mumbai, India.

2.2. Methods

2.2.1. Calculation of Solubility Parameter (\( \delta \)), Glass Transition Temperature (\( T_g \)), and Flory-Huggins Parameter (\( \chi \)). As an indicator of the drug-polymer miscibility, values of \( \delta \) were calculated using the Hoftyzer and vanKrevelen group contribution method described by the following equation:

\[
\delta^2 = \delta^2_d + \delta^2_p + \delta^2_h, 
\]

\[
\delta_d = \frac{\sum F_{g1}}{V}, \quad \delta_p = \left( \frac{\sum F_{g2}}{V} \right)^{1/2}, \quad \delta_h = \left( \frac{\sum F_{h2}}{V} \right)^{1/2}. 
\]

Here \( i \) is the groups within the molecule, \( \delta \) is the total solubility parameter, \( \delta_d \) is the contribution from dispersion forces, \( \delta_p \) is the contribution from polar interactions, \( \delta_h \) is the contribution of hydrogen bonding, \( F_{g1} \) is the molar attraction constant due to molar dispersion forces, \( F_{g2} \) is the molar attraction constant due to molar polarization forces, \( h_2 \) is the hydrogen bonding energy, and \( V \) is the molar volume. The solubility parameters of polymer and surfactant combinations were calculated using the following equation:

\[
\delta_{1,2} = V' \delta_1 + V'' \delta_2, 
\]

where \( V' \) is the volume fraction of each compound.

Miscibility of the drug with the polymer can be assessed based on the shift in melting endotherm or \( T_{g1} \) of the drug or can be predicted theoretically using Gordon-Taylor equation based on the \( T_{g1} \) densities, and weight fractions of the components. Consider

\[
T_{g \text{mix}}(\text{HME system}) = W_1 T_{g1} + K W_2 T_{g2} + K W_2 W_1, 
\]

\[
K = \frac{T_{g1}P_1}{T_{g2}P_2}, 
\]

where \( T_{g1} \) is the glass transition temperature of drug, \( W_1 \) and \( W_2 \) are the weight fractions of the components, and \( K \) is the parameter calculated from the true densities (\( \rho_1 \) of drug and \( \rho_2 \) of polymer) and \( T_{g2} \) of the amorphous components [16]. The true density measurement of the PCZ and polymers was determined in duplicate using a gas displacement pycnometer (Accupyc 1330; Micromeritics, Norcross, Georgia).

The Flory-Huggins (FH) interaction parameter (\( \chi \)) was calculated using the following equation:

\[
\frac{1}{T_{m \text{mix}}} - \frac{1}{T_{m \text{pure}}} = - \frac{R}{\Delta H_f} \left\{ \ln \Phi_{\text{drug}} + \left( 1 - \frac{1}{m} \right) \Phi_{\text{polymer}} + \chi \Phi_{\text{polymer}}^2 \right\}, 
\]
Table 1: HME process parameters and drug-polymer composition of prepared formulations.

| Formulation codes | Batch size (gm) | Drug (gm) | Sol (gm) | PEG400 (gm) | LF127 (gm) | LF68 (gm) | TPGS (gm) | Extrusion temp. (°C) (speed 50 rpm for all) | Residence time (min) |
|-------------------|----------------|-----------|----------|-------------|------------|----------|----------|------------------------------------------|---------------------|
| PZ1               | 60             | 30        | 29       | 1           | —          | —        | —        | 115                                      | 7–9                 |
| PZ2               | 60             | 30        | 29       | —           | 1          | —        | —        | 114                                      | 9–11                |
| PZ3               | 60             | 30        | 29       | —           | —          | 1        | —        | 118                                      | 10–12               |
| PZ4               | 60             | 30        | 29       | —           | —          | —        | 1        | 112                                      | 8–10                |

where $T_m^{mix}$ is the melting temperature of the drug in the presence of the polymer, $T_m^{pure}$ is the melting temperature of the drug in the absence of the polymer, $\Delta H_f$ is the heat of fusion of the pure drug, $m$ is the ratio of the volume of the polymer to PCZ, and $\Phi_{drug}$ and $\Phi_{polymer}$ are the volume fractions of the drug and the polymer, respectively [17].

2.3. Development of SD Using HME. Uniform mixing of drug with the polymer-surfactant in 1:1, 1:2, and 1:3 ratios was executed in a mortar-pestle to prepare physical mixtures (PMs) of 60 g each. The PMs were then transferred to a turbula mixer and further mixed for 15 min to ensure homogenous mixing. Hot melt extrusion was performed by using lab scale single screw extruder fabricated by S.B. Panchal pvt. Ltd. (Mumbai, India). Thermal parameters and speed of extruder were kept constant throughout the process for respective samples. The mixture takes about 3–5 minutes to form molten mass between walls of the screw and extruder barrel. Residence time was about 8–15 minutes for extruded to come out for various samples. The hot melt extrudates were collected, allowed to cool, milled using mixer grinder, and screened through sieve of mesh number 100. The powdered SD were stored in 50 cc amber colored glass bottles in a desiccator at room temperature and 0% humidity for further analysis and characterisation. Overall 12 optimized formulation batches were practically carried out having drug to polymer ratio 1:1, 1:2, and 1:3. In current paper, prepared SD formulations containing drug to polymer in 1:1 ratio has been discussed. Physicochemical, analytical and in vivo performance of the same is reported as SD (1:1 in ratio) has 50 % drug loading [18].

2.4. Physical State Characterization

2.4.1. Differential Scanning Calorimetry (DSC) and (M-DSC). Thermal analysis was performed by using PYRIS-1 Differential Scanning Calorimeter (DSC) (Perkin Elmer, USA) equipped with a liquid nitrogen attachment to study the drug and SD crystalline variability. During M-DSC accurately weighed samples (4-5 mg) were placed in sealed aluminum pans and a heat-cool-cycle applied involving heating from 40 to 260°C at 10°C/min then rapidly cooling to 40°C and then reheating to 260°C at 10°C/min.

2.4.2. Powder X-Ray Diffractometry (PXRD). X-ray diffraction patterns were recorded using Advance D8 system with CuKα radiation instrument (Bruker, USA). The recording spectral range was set at 0–60° (2θ) using the Cu-target X-ray tube and Xe-filled detector.

2.4.3. FT-IR Spectroscopy. Pure PCZ and SD were analysed by using a Fourier transform infrared spectrophotometer model 4100 (Spectrum GX–FT-IR, Perkin Elmer, USA).

2.4.4. Scanning Electron Microscopy (SEM). The shape and surface morphology of the crystalline PCZ and PCZ-loaded SD were examined using XL 30 Model JEOL 6800 scanning electron microscope made in Japan during analysis.

2.4.5. Raman Spectroscopic Analyses. The Raman spectra of the SD were recorded with a LabRamHR800 (Horiba Jovian Yvon) equipped with a 633 nm Ar-Ne laser. The laser excitation was focused using 50 objectives (Olympus Corporation) and the scattered light was totally transmitted through the notch filter towards the confocal hole and entrance slit of the spectrograph [19].

2.4.6. Atomic Force Microscopy (AFM) Characterization. JXA-8530F Hyper Probe Electron Probe Microanalyzer instrument by JEOL was employed for AFM analyses. Freshly fractured extrudates on microscopic glass slides were mounted on the micrometre positioning stage of a Dimension Icon AFM with accelerating voltage of 1-30 kV. Probe current range was kept between 10 pA and 200 pA and back scattered electron images were obtained [20].

2.4.7. Molecular Modelling Studies. The monomer unit structures of polymer Sol, LF127, LF68, TPGS, and PCZ were constructed by using Gaussian programme in Schrodinger, maestro software programme, USA. The energy minimization, docking, and MD-simulation studies of different conformations of drug-polymer were run to understand the structural interaction and to identify most stable conformation of drug with polymer [21, 22].

2.5. HPLC Analyses. PCZ and SD contents were determined using a Binary HPLC pump and 2998 UV Array detector (Agilent Corporation, Milford, Massachusetts). The formulación codes are given as PZ1, PZ2, PZ3, and PZ4 (see Table 1 for details). Mobile phase composed of methanol-water (75 : 25, v/v), at 1.0 mL min⁻¹ flow rate, was used. The injection volume was 20 μL and detection was at 262 nm for PCZ and SD [23, 24].
2.6. In Vitro Dissolution Studies. Quantity equivalent to 100 mg of PCZ was weighed from powdered SD filled inside the hard gelatine capsule that was used for the dissolution studies. The PCZ SD and marketed suspension Noxafil were investigated for their dissolution behavior. Dissolution studies were performed as per USFDA reported method, in the 900 mL with 0.3% SLS medium (sodium lauryl sulphate) at 37±0.2°C using a paddle USP type II apparatus (Electrolab DBK, Mumbai, India) at speed of 25 rpm. PCZ released from the SD and Noxafil was characterised by UV absorbance measurement at a wavelength of 262 nm [25].

2.7. In Vivo Pharmacokinetics after Oral Administration

2.7.1. Animals and Dosing Protocol. A single dose bioavailability study was designed in Wistar rats under fasting conditions. The animal experiments were implemented by the guidelines of the Committee for the Purpose of Control and Supervision of Experimental Animals (CPCSEA), India. The experimental protocol was approved by Institutional Animal Ethics Committee (IAEC) of Institute of Chemical Technology (Protocol number ICT/IAEC/2013/P02). Healthy male Wistar rats (weighing 170–200 g) (procured from Haffkine Institute, Mumbai, India) were used for the study. The animals were randomly divided into four groups (n = 6), namely, pure PCZ, Noxafil, PZ1-SD, and PZ2-SD. All rats received oral doses of 10 mg/kg including PCZ pure, marketed Noxafil suspension, and PCZ SD powder. The formulations were dispersed in pure water and then immediately administered to the rats by oral gavage according to the concentration of PCZ in the formulations. Six animals were used for each formulation. Blood samples (~0.5 mL) were drawn by retroorbital venous plexus puncture at 15 and 30 min and 1, 2, 4, 6, 8, 12, 24, 36, 48, and 72 h following oral administration after dose. Aliquots of 0.5 mL of blood were withdrawn in micro centrifuge tube previously containing acid-citrate-dextrose (ACD) buffer (0.2 mL) as an anticoagulant. The plasma blood samples were centrifuged under refrigeration at 7000 rpm for 10 min and stored at −20°C until further analyzed by HPLC. The animal study was carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki).

2.7.2. HPLC Quantification of PCZ in Plasma Samples. HPLC method was developed for the analysis of PCZ in plasma of rats, a species used for safety evaluation. The HPLC analysis involved protein precipitation with methanol followed by separation on column and quantitation by UV absorbance at 262 nm. The method was sensitive with a limit of quantification of 0.25 µg/mL in rat plasma. Calibration curves were used for the conversion of the PCZ/PCZ chromatographic area to the concentration of PCZ. Calibrator and quality control samples were prepared by adding appropriate volumes of standard PCZ solution in acetonitrile to drug free plasma. Calibration curves ranged from 6.4 to 36.6 µg/mL (r² = 0.997). Briefly, an aliquot (100 µL) of plasma sample was mixed with 50 µL of IS solution (Itraconazole 100 µg/mL) and 50 µL of drug solution. After vortexing for 30 sec a protein precipitating agent methanol (500 µL) was added and vortexed for 1 min. The mixture was centrifuged (Eltek TC 4100 D 232 centrifuge) at 7000 rpm for 15 min. The supernatant was filtered through 0.22 µm syringe driven membrane filter unit and 50 µL of the filtrate was injected onto the HPLC system. The mobile phase consisted of 0.09 M ammonium phosphate monobasic acetonitrile-triethylamine (55:45 v/v) and was delivered at 1 mL/min.

2.7.3. Pharmacokinetic Data Analysis. The pharmacokinetic analysis of plasma concentration-time data was analyzed by one compartmental model, using Kinética software (Thermo Scientific). Required pharmacokinetics parameters such as total area under the curve AUC(0−72), half-life (t1/2), peak plasma concentration (Cmax), and time to reach the maximum plasma concentration (Tmax) were determined.

2.8. Contact Angle Evaluation Studies. The contact angle measurement was performed using G10 Contact angle meter (Kruss, Germany) to evaluate the wetting property of prepared system compared to pure hydrophobic drug PCZ. A solid disc with flat surface (100 mg) was prepared of pure PCZ and the optimized SD PZ1, PZ2, PZ3, and PZ4. A drop of distilled water was dropped on the disc surface and contact angle was measured immediately and after 60 sec of equilibrium. Three samples were measured from each batch.

2.9. Stability of Prepared SD. Prepared SD were kept inside the closed glass vials under controlled temperature environment inside stability chamber (Thermo Lab, India) with relative humidity of 35%, 60%, and 75% RH and temperature 37°C, 40°C, and 60°C for stability studies. Samples were removed after 1, 3, and 6 months, evaluated for dissolution rate study, and compared with those SD tested immediately after preparation [26]. The assay of the drug and SD was evaluated using HPLC at λ = 262 nm.

3. Results and Discussion

3.1. Mathematical Calculations. If Δδ is less than 7 MPa1/2 both components are miscible. When Δδ value was ≥10 MPa1/2, incompatibility and phase separation between drug and polymer occurs. The calculated solubility parameters are presented in Table 2. The calculated differences between δ (i.e., Δδ) values of PCZ and Surfactant blend were found to be in the range 2.67–4.5 MPa1/2, being less than 7 MPa1/2 indicating likely miscibility. The results suggest that Δδ values are useful parameters in predicting miscibility and polymer selection for HME process [27]. Incomplete miscibility or reduced solubility can result in the formation of concentrated drug spheres that may lead to recrystallization after production and during stability [28]. From the results obtained theoretically by Gordon-Taylor analysis is found to be in similar range of experimental Tw (temperature used for HME process) as shown in Table 3. From the results, calculated value of FH interaction factor (χ) is not ≥0.5/M which signifies higher favorable extent of drug-polymer
Table 2: Solubility parameter calculation for drug polymer compatibility.

| Drug and polymers | δ_sdi | δ_pdi | δ | Δδ MPa^{1/2} (not ≥ 7) | Drug-polymer compatibility |
|-------------------|-------|-------|---|-------------------------|---------------------------|
| PCZ              | 9.04  | 3.11  | 15.93 | 18.57 (a)               | —                         |
| Sol + PEG400     | (19.43 + 9.60)/2 | 14.51 (b) | (a – b) = 4.06 | Miscible                |
| Sol + LF127      | (19.43 + 11.20)/2 | 15.31 (c) | (a – c) = 3.26 | Miscible                |
| Sol + LF68       | (19.43 + 12.37)/2 | 15.9 (d) | (a – d) = 2.67 | Miscible                |
| Sol + TPGS       | (19.43 + 8.71)/2 | 14.07 (e) | (a – e) = 4.5 | Miscible                |

Table 3: Shows the Gordon-Taylor equation calculated $T_{g\text{mix}}$ of SD systems.

| Formulation codes | $W_1$ | $T_{g1}$ | $W_1 * T_{g1}$ | $w_2$ | $T_{g2}$ | $W_2 * T_{g2}$ | $\rho_1$ | $\rho_2$ | $T_{g1} * \rho_1$ | $T_{g2} * \rho_2$ | $w_1 + k w_2$ | $T_{g\text{mix}}$ |
|-------------------|-------|---------|----------------|-------|---------|----------------|---------|---------|-------------------|-------------------|---------------|----------------|
| PZ1               | 0.5   | 176.34  | 88.17          | 2     | 115     | 230            | 1.3     | 0.86    | 221.13            | 98.94             | 4.971         | 121.16         |
| PZ2               | 0.5   | 176.34  | 88.17          | 2     | 114     | 228            | 1.3     | 0.86    | 221.13            | 98.04             | 5.011         | 120.22         |
| PZ4               | 0.5   | 176.34  | 88.17          | 2     | 118     | 236            | 1.3     | 0.86    | 221.13            | 101.48            | 4.858         | 124.00         |
| PZ4               | 0.5   | 176.34  | 88.17          | 2     | 112     | 224            | 1.3     | 0.86    | 221.13            | 96.32             | 5.091         | 118.31         |

interactions at micro level. [29]. Adhesive interaction between drug and polymer favoured by the reduction in the $T_g$ of SD systems which implicate the miscibility of drug and polymer is shown in Table 4.

3.2. Solid State Characterization

3.2.1. Thermal Investigation Using DSC, MDSC, and XRD. Solid-state extruded SD was analysed using DSC and MDSC. DSC was used to determine the PCZ state in the extruded SD and to identify possible drug-polymer interactions. Figure 1 depicts the thermograms of pure PCZ which clearly show endothermic sharp peak at 176.34°C. DSC thermographs of PM show characteristic peak of crystalline PCZ. The thermograms of the hot melt extrudates SD showed different thermal behaviour for PCZ. As shown in Figure 1, the drug melting endotherms disappeared completely in case of SD. The absence of PCZ endotherms suggests either drug solubilization due to the presence of used excipients or being present in an amorphous state. Thus, it was concluded that PCZ converted to its amorphous form during hot melt processing approach. MDSC studies were performed to recognize the stable nature of amorphous SD of PCZ prepared by HME. Compared to the sharp melting peak of pure PCZ, the endothermic peaks in SD broadened during the first heating cycle and then disappeared in the second heating cycle. This is caused by gradual dissolution of the crystalline drug in the molten polymers and complete conversion to the amorphous state during the DSC heating process. MDSC shows the respective $T_g$ of SD prepared approximately in similar range of temperature which signifies the amorphous drug nature in SD Figure 2. The prepared SD formulations were found to be stable in amorphous state after 6 months. The physical state of PCZ was further investigated by employing X-ray powder diffraction.

XRD of PCZ consist of sharp multiple peaks, indicating the crystalline nature of the drug with specific % crystallinity. In the XRD of PCZ peak intensities are observed at 10.23, 13.22, 13.82, 15.24, 16.11, 18.34, 19.27, 21.62, 22.14, 23.55, 23.64, 24.92, 26.12, 27.42, 30.86, 32.13, 35.11, and 46.23. Characteristic peaks intensities of PCZ are observed at 8100, 7500, 5500, 4300. In the case of SD (about 2 gm), when exposed to X-ray beam, it shows disappearance of most of the crystalline endothermic peak and characteristic intensities of PCZ. This indicates complete transformation of crystalline PCZ into amorphous form during HME process. From the XRD studies of both fresh and aged SD systems amorphous nature of PCZ after HME was confirmed. The observed few intensity peaks in the diffractograms are attributed to the SD excipients such as PEG400, LF127, LF68, and TPGS as shown in Figure 3. The diffractograms indicate that PCZ is in amorphous state (or molecularly dispersed) in the SD. The XRD results are in good agreement with those of DSC thermograms.

3.2.2. FTIR. Possible interactions between drug and polymer in SD were investigated by FTIR. FTIR spectra of PCZ and SD were examined. FTIR spectra are properly labeled and shown in Figure 4. IR of pure PCZ characteristic has absorbance at 3857.04 cm^{-1} and 3274.12 cm^{-1}. A selective stretching vibration at 1637 cm^{-1} due to saturated ketone and C=O–NH stretching at 3041.89 cm^{-1} and also exhibited C=O stretch at 1762.36 cm^{-1} due to saturated ketone and C=O–NH stretching at 1637 cm^{-1}. A selective stretching vibration at 1555.35 cm^{-1} and 1617 cm^{-1} for secondary and tertiary amine was also observed. For functional groups like C–O stretch and –C–F stretch they showed vibrations at 1054.24 cm^{-1} and 1008.08 cm^{-1}, respectively. Most of the peaks that are observed in the spectral region 765–791 cm^{-1} are due to stretching (bending =C–H) vibrations. The IR spectra of PZ1 showed characteristic peaks at 2913.25 cm^{-1}, 1731.02 cm^{-1}, 1765.35 cm^{-1}, 1731.46 cm^{-1}, 1083.40 cm^{-1}, 841.98 cm^{-1}, 716.78 cm^{-1}, 604.86 cm^{-1}, and 570.72 cm^{-1}. The IR spectra of PZ2 and PZ3 showed characteristic peaks at 3854.48 cm^{-1}, 1602.19 cm^{-1}, 1384.67 cm^{-1}, 1078.46 cm^{-1}, 714.02 cm^{-1}, 3400.8 cm^{-1}, 1731.75 cm^{-1}, 1595.9 cm^{-1}, 1384.73 cm^{-1}, 1160.72 cm^{-1}, 841.16 cm^{-1}, and 713.49 cm^{-1}. In the XRD of PCZ peak intensities are observed at 10.23, 13.22, 13.82, 15.24, 16.11, 18.34, 19.27, 21.62, 22.14, 23.55, 23.64, 24.92, 26.12, 27.42, 30.86, 32.13, 35.11, and 46.23. Characteristic peaks intensities of PCZ are observed at 8100, 7500, 5500, 4300. In the case of SD (about 2 gm), when exposed to X-ray beam, it shows disappearance of most of the crystalline endothermic peak and characteristic intensities of PCZ. This indicates complete transformation of crystalline PCZ into amorphous form during HME process. From the XRD studies of both fresh and aged SD systems amorphous nature of PCZ after HME was confirmed. The observed few intensity peaks in the diffractograms are attributed to the SD excipients such as PEG400, LF127, LF68, and TPGS as shown in Figure 3. The diffractograms indicate that PCZ is in amorphous state (or molecularly dispersed) in the SD. The XRD results are in good agreement with those of DSC thermograms.
Table 4: Florey Huggins interaction parameter (χ) of SD.

| Ratio | 1/T mix | 1/T pure | LHS | R | ΔHf | R/ΔHf | Φ drug | m | 1/m | 1 − 1/m | Φ Polymer | log(Φ drug) | ln Φ drug + 1 − 1/m | Φ Polymer | Φ2 Polymer | R/ΔHf (ln Φ drug + 1 − 1/m) | Φ2 Polymer | Left | X |
|-------|---------|----------|-----|---|-----|--------|--------|---|-----|--------|-----------|-----------|-----------------|-----------|-----------|----------------------------|-----------|------|---|
| PZ1   | 0.008695652 | 0.005670863 | 0.003025 | 8.314 | 69.084 | −0.1204683 | 0.5 | 2 | 0.5 | 0.5 | 1 | 0.5 | −0.30103 | 0.19897004 | 1 | −0.02396958 | −0.120468311 | 0.00302 | −0.025 |
| PZ2   | 0.00877193 | 0.005670863 | 0.003104 | 8.314 | 69.084 | −0.1204683 | 0.5 | 2 | 0.5 | 0.5 | 1 | 0.5 | −0.30103 | 0.19897004 | 1 | −0.02396958 | −0.120468311 | 0.00301 | −0.026 |
| PZ3   | 0.008474576 | 0.005670863 | 0.002804 | 8.314 | 69.084 | −0.1204683 | 0.5 | 2 | 0.5 | 0.5 | 1 | 0.5 | −0.30103 | 0.19897004 | 1 | −0.02396958 | −0.120468311 | 0.00328 | −0.023 |
| PZ4   | 0.008928571 | 0.005670863 | 0.003258 | 8.314 | 69.084 | −0.1204683 | 0.5 | 2 | 0.5 | 0.5 | 1 | 0.5 | −0.30103 | 0.19897004 | 1 | −0.02396958 | −0.120468311 | 0.00326 | −0.027 |
The IR spectra of PZ4 showed characteristic peaks at 3033.34 cm\(^{-1}\), 2884.20 cm\(^{-1}\), 2282.09 cm\(^{-1}\), 2220.09 cm\(^{-1}\), 1730.23 cm\(^{-1}\), 1462.58 cm\(^{-1}\), 1133.04 cm\(^{-1}\), 974.11 cm\(^{-1}\), 838.27 cm\(^{-1}\), 716.15 cm\(^{-1}\), 676.84 cm\(^{-1}\), and 571.58 cm\(^{-1}\). The IR spectra of SD signify the presence of drug and no change in its functional properties. The addition of polymer and surfactant during HME process would not affect PCZ molecule stretching vibrations. Interaction between the polymer and drug in SD mixtures formed molecular dispersions with slight shifting of specific intensities compared to pure PCZ IR spectrum. The carbonyl group is more favourable for hydrogen bonding and intermolecular interactions than the nitrogen atom because of steric hindrance. For SD, the –OH stretching bands broadened and the intensity of the bands decreased to minimal, indicating specific degree of interaction between the proton donating groups of PCZ and the proton accepting groups in the Sol.

3.2.3. SEM. SEM micrograph of pure PCZ consists of large crystalline form of drug agglomerates with ordered shape and size, Figure 5(a). SEM of SD showed intrinsic miscibility of drug and polymer interface at micro level. However, in SD systems presence of relatively rough surface also suggests that hydrophilic polymer and surfactant were spread uniformly on the surface of the drug as shown in Figures 5(b), 5(c), 5(d), and 5(e). The PCZ SD appeared to be agglomerated with rough surface owing to the miscibility of drug into polymer.
Figure 4: Continued.
**Figure 4**: Infrared spectroscopic diagrams of pure PCZ and SD systems.

**Figure 5**: SEM images with surface morphology of pure PCZ (a), PZ1 (b), PZ2 (c), PZ3 (d), and PZ4 (e).
Figure 6: Continued.
3.2.4. Raman Analyses. With Raman spectroscopy, a laser photon is scattered by sample molecule and loses (or gains) energy during the process. The intensity of spectral features in solution is directly proportional to the concentration of the particular species as shown in Figure 6(a). Raman spectroscopy and its imaging technique are useful tools to evaluate crystal and amorphous states, including discrimination of crystalline drug in SD as shown in Figure 6(b). It confirms the presence of drug in amorphous form in SD and its uniform distribution [30]. Images of the amorphous regions in SD are described by the width at half maximum around 1150 and 1300 cm$^{-1}$ (green area was thought to be due to amorphous drug).

3.2.5. AFM Analyses. Fractured fresh extrudate with smooth surfaces are used for microscopic investigations using AFM. Fracture surfaces were generated at determined fracture points on the outer surfaces of the extrudates. All extrudates had the form of transparent cylindrical rods; 2 and 3.5 cm long and of 1 cm width were selected and placed on a sheet of paper. The freshly fractured extrudates were mounted on an optical glass slide by use of a 2-component epoxy resin, which hardened within ~5 min. Before the hardening reaction had been completed the extrudeate orientation was corrected to get the fracture surface as horizontal as possible. This step is mandatory to enable nondestructive imaging and automated sample changing within AFM operations [31]. Freshly fractured extrudates on microscopic glass slides were mounted on the micrometre positioning stage of a Dimension Icon AFM. Between 10 and 25 regions per sample were programmed to be automatically characterized using the software routine “programmed move” in tapping mode. Height, phase, and amplitude images were collected simultaneously, using etched silicon cantilevers with a nominal spring constant of $k = 40−100$ N/m (JEOL AFM Probes). The typical free vibration amplitude was in the range of $A = 10$ to 50 nm; the images were recorded with set-point amplitudes corresponding to 60–70% of the free amplitude. Image areas of $10 \times 10$ mm were recorded at a resolution of 1,024 × 1,024 pixels. All data were batch-processed using Scanning Probe Image Processor (SPIP 5.1.1). Height data were plane-corrected by applying a 3rd order polynomial fit [32]. Molecular fracture roughness data is also displayed in Figure 7. 3D surface AFM imaging analysis of SD formulations helps to understand the drug-polymer surface morphology as well as interaction. The roughness parameters reflect the % variation...
with respect to the topography mean height. It indicates from the AFM analysis that there is high level of surface interaction and amorphization of drug inside polymer matrix observed in extrudes.

3.3. Molecular Dynamic Simulation Studies. After energy minimization of drug and polymer strong hydrogen bonding interactions were identified. The stable conformation with lowest energy values was optimised and MD simulation dynamics was started. MD-simulation studies revealed the strong drug-polymer interactions. The effect of PEG400, LF127, LF68, and TPGS on the interaction between PCZ along with Sol was found to be favorable. The stable conformations obtained after molecular dynamic simulation showed different geometric arrangement of the molecules. The most stable was found to be Figure 8(a) with lowest energy and highest bonding interaction between drug and polymer [33, 34].

3.4. In Vitro Dissolution Studies. Higher apparent drug solubility and improved dissolution profiles are attributed to the amorphous nature of PCZ in SD system where PCZ is molecularly dispersed in the polymer matrix. Lattice energy of SD system is due to short range intermolecular interaction in amorphous system. When drug in SD dissolves then change in lattice energy is not destructed by the drug itself so the dissolution rate improved. Dissolution profiles of various SD are as shown in Figures 9(a) and 9(b). The dissolution of the SD with different formulations like PZ1 = 100.26%, PZ2 = 97.26%, PZ3 = 84.45%, and PZ4 = 100.25%, at the end of $T_{10}$ minutes, was approximately 45.99-, 44.61-, 38.74-, and 45.98-fold higher than pure PCZ, respectively. The dissolution of the SD in water (PZ1 = 71.25%, PZ2 = 61.25%, PZ3 = 52.33%, and PZ4 = 67.55% at $T_{60}$ minutes) was approximately 80.05-, 68.82-, 58.79-, and 75.89-fold than pure PCZ. The marketed suspension Noxafil dissolution studies are also carried out which are found to be inferior in terms of dissolution as compared to prepared SD. Dissolution rate of the drug in Sol-surfactant systems is governed by solubilization of the polymer to create a hydrotropic environment for the insoluble drug. It was observed that of the Sol-surfactant SD dissolved rapidly. The high dissolution rate of PCZ from the Sol-PEG400, Sol-LF127, Sol-LF68, and Sol-TPGS dispersion is believed to be due to the drug-polymer molecular intermixing at micro level. The aqueous solubility
and dissolution rate of prepared SD were also significantly enhanced. In comparison to pure PCZ, the dissolution rate of physical mixtures was slightly increased probably because the hydrophilic polymer can wet the surface of drug particles and act to solubilize them. The dissolution of SD was enhanced with total release occurring within 10 min. This clearly shows that a remarkable improvement in dissolution performance was achieved by HME. From the dissolution profiles it is evident that HME processing can be employed for the manufacture of PCZ immediate release SD by processing polymer-surfactant combination. The preferred dissolution patterns can be achieved through the drug loading percentage and the extrusion process. The extrusion appeared to be an effective approach for the development of diffusion controlled SD of PCZ [35].

3.5. In Vivo Pharmacokinetic Study. Figure 10 shows the mean plasma concentration-time curves of PCZ, after administration by oral gavage of crystalline PCZ, PCZ suspension (Noxfil), PZ1, and PZ4 SD powder to rats. The pharmacokinetic parameters are listed in Table 5. The PCZ/Sol/PEG400 (PZ1) and PCZ/Sol/TPGS (PZ4) SD had enhanced bioavailability. This was increased compared with the PCZ suspension although they all improved the bioavailability compared with pure crystalline PCZ. Also, the $T_{\text{max}}$ of PZ1 and PZ4 SD was prior than that of PCZ suspension. This happened due to passive transport of PCZ across the membrane in presence of Sol. This was also correlated with the dissolution profile results which claims that the dissolution rate of PZ SD was faster than that of PCZ suspension. When passing through the GI tract, the amorphous PCZ in SD was quickly dissolved and absorbed into blood circulation. PCZ primarily circulates as the parent compound in plasma. The $T_{\text{max}}$ of PZ1 and PZ4 SD was reached earlier at 1h with plasma PCZ concentration of 317.97 ng/mL and 265.36 ng/mL, respectively, which indicates bioavailability enhancement. From Table 5, it can be seen that there was a significant difference between PZ1 SD and crystalline PCZ with the former having 11.6 times higher $AUC_{(0-72)}$ than PCZ and 17.7 times higher $C_{\text{max}}$ than PCZ, respectively. The corresponding results for PCZ suspension were having 4.9 times higher $AUC_{(0-72)}$ than PCZ and 6.2 times higher $C_{\text{max}}$ than PCZ, respectively. The significant enhancement in the bioavailability of PCZ was achieved by the PCZ/Sol SD prepared by the HME process. Also, it is reported that the food intake improves the bioavailability of PCZ. Supersaturation had a marked effect in which a high energy drug and used surfactants act as precipitation inhibitors which are induced by the gastrointestinal pH gradient. Hence, this may result in supersaturated concentrations and an increased flux across the membrane. It was also

![Figure 8: MD simulation stable conformations of PCZ-Sol-PEG400 (a), PCZ-Sol-LFI27 (b), PCZ-Sol-LF68 (c), and PCZ-Sol-TPGS (d).](image-url)
Figure 9: (a) *In vitro* release of SD systems in medium of 0.3% SLS (mean ± SD (n = 3)); (b) *in vitro* release of SD systems in distilled water (mean ± SD (n = 3)).

**Table 5:** *In vivo* pharmacokinetic parameters of the PCZ, Nozafil, PZ1, and PZ4 tested.

| Parameters | PCZ crystalline | Nozafil | PZ1 SD | PZ4 SD |
|------------|-----------------|---------|--------|--------|
| $C_{\text{max}}$ (ng/mL) | 27.42 ± 11.26 | 134.74 ± 47.24 | 317.97 ± 14.58 | 265.36 ± 22.35 |
| $T_{\text{max}}$ (h) | 6 ± 1.22 | 5 ± 1.31 | 1 ± 1.25 | 1 ± 1.37 |
| AUC$_{0-72}$ (ng h/mL) | 880.35 ± 124.35 | 4707.28 ± 245.14 | 10159.64 ± 1024.56 | 8354.28 ± 786.69 |
| $t_{1/2}$ (h) | 18.24 ± 2.34 | 25.38 ± 3.75 | 25.12 ± 1.66 | 25.87 ± 2.44 |

Figure 10: *In vivo* plasma drug concentration-time curve of PCZ, Nozafil, PZ1 SD, and PZ4 SD.

proved by the *in vitro* dissolution study that the SD showed improved dissolution, which allows further solubilization by endogenous substances like biliary fluids. Apparently, this phenomenon plays an important role in the absorption of PCZ in SD. Compared with the PCZ suspension, the higher degree of supersaturation obtained with amorphous PCZ in the SD showed a significant enhancement in oral absorption. The Soluplus and added surfactants also act as stabilizer for supersaturation upon drug release by inhibiting precipitation. These factors all increase the oral absorption and, consequently, the bioavailability of PCZ to several folds as compared to PCZ suspension and crystalline PCZ. Amorphous PCZ SD prepared using HME was found to be effective therapy with beneficial improvement in therapeutic activity of PCZ [36–38].

3.6. Statistical Analysis. All the results were expressed as mean ± standard deviation (SD). Statistical analysis was performed with Sigma Stat (Version 2.03) using one-way ANOVA test with $P < 0.05$ which was considered as statistically significant difference.

3.7. Contact Angle Calculation. The contact angle is the angle formed by the solid/liquid interface and the liquid/vapor interface measured from the side of the liquid. Contact angle also is a term used to describe a process where a drop of liquid is in contact with a solid surface and exhibits its angle towards the surface. By analyzing the contact angle, we can relate the values with the ratio and solubility and wettability of the drugs. Disc made from pure PCZ showed higher contact angle after 60 sec of equilibrium whereas SD system showed very less contact angle after equilibrium time. This effect attributed to presence of hydrophilic polymer matrix and soluble state of drug inside the system. Low contact angle value indicates highly improved wetting property of PCZ in SD system as shown in Table 6.

3.8. Stability on Storage. SD is thermodynamically metastable system that favours the conversion of amorphous form to the crystalline form under storage. To evaluate the physical
Table 6: Contact angle measurement of pure PCZ and SD formulations.

| Formulation codes (SD) | Contact angle (θ) |
|------------------------|------------------|
|                        | $t = 0$ sec | $t = 60$ sec |
| PZ1                    | 2.5 ± 0.2   | 1.1 ± 0.2   |
| PZ2                    | 3.3 ± 0.4   | 1.6 ± 0.5   |
| PZ3                    | 3.2 ± 0.3   | 1.4 ± 0.4   |
| PZ4                    | 2.8 ± 0.5   | 1.2 ± 0.2   |
| Pure PCZ               | 93 ± 0.8    | 86 ± 0.6    |

state of the drug, the systems were characterized by XRD and DSC after storage for 6 months. The systems were stable during a 6-month period. In the case of SD, no substantial recrystallization was observed by DSC or XRD over the 6 months storage suggesting that PCZ is more stable in this formulation.

4. Conclusions

In the current study it was clearly demonstrated that PCZ immediate release SD formulation can be effectively produced by processing via HME with dissolution rate, solubility, and bioavailability enhancement. Novel polymer-surfactant combinations were optimised and stable SD systems were developed successfully. Utilization of Soluplus along with suitable surfactants offers excellent possibilities to develop stable amorphous SD. Selective use of surfactants with low concentrations improves process workability, increases melt viscosity with torque reduction, reduces $T_g$ of blend, augments quality of extrudes, and reduces residence time of extrusion. The study revealed the importance of suitable carrier and processing technique selections are critical parameters during HME. AFM analyses revealed microscopic surface interaction between drug and polymer. MD simulation studies revealed possible molecular interaction between drug-polymer. Furthermore, this PCZ-incorporated SD gave higher dissolution compared to the commercial product and pure PCZ powder. In vivo bioavailability of hot melt extruded PCZ SD formulations showed several fold enhancements as compared to that of Noxfail suspension and pure PCZ. This improved therapeutically active formulation which helps to cure opportunistic invasive infections more effectively.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are thankful to UGC (SAP) for providing the research fellowship and Institute of Chemical Technology, ELITE status (Mumbai, India), for providing all facilities and guidance. The authors are thankful to S.A.I.F. department at Indian Institute of Technology, Mumbai, for Raman spectroscopic experimental help and analyses. The authors are thankful to Mr. Madhav Seervi (PhD Fellow) from Pharmacology Department, Institute of Chemical Technology, for help in animal studies.

References

[1] S. Guns, V. Mathot, J. A. Martens, and G. van den Mooter, “Upscaling of the hot-melt extrusion process: comparison between laboratory scale and pilot scale production of solid dispersions with miconazole and Kollicoat IR,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 81, no. 3, pp. 674–682, 2012.
[2] R. Fule, T. Meer, P. Amin, D. Dhamecha, and S. Ghadlinge, “Preparation and characterisation of lornoxicam solid dispersion systems using hot melt extrusion technique,” Journal of Pharmaceutical Investigation, vol. 44, no. 1, pp. 41–49, 2014.
[3] K. Zhang, H. Yu, Q. Luo et al., “Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, pp. 1285–1292, 2013.
[4] J. Djuris, I. Nikolakakis, S. Ibric, Z. Djuric, and K. Kachrimanis, “Preparation of carbamazepine-soluplus solid dispersions by hot-melt extrusion, and prediction of drug-polymer miscibility by thermodynamic model fitting,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 84, no. 1, pp. 228–237, 2013.
[5] R. Fule, T. Meer, A. Sav, and P. Amin, “Artemether-Soluplus hot-melt extrudate solid dispersion systems for solubility and dissolution rate enhancement with amorphous state characteristics,” Journal of Pharmaceutics, vol. 1, pp. 1–15, 2013.
[6] C. Vo, C. Park, and B. Lee, “Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, pp. 799–813, 2013.
[7] I. Tho, B. Liepold, J. Rosenberg, M. Maegerlein, M. Brandl, and G. Fricker, “Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media,” European Journal of Pharmaceutical Sciences, vol. 40, no. 1, pp. 25–32, 2010.
[8] M. Zhang, H. Li, B. Lang et al., “Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 82, no. 3, pp. 534–544, 2012.
[9] R. Fule, T. Meer, A. Sav, and P. Amin, “Solubility and dissolution rate enhancement of lumezantrine using hot melt extrusion technology with physicochemical characterisation,” Journal of Pharmaceutical Investigation, vol. 43, no. 4, pp. 305–321, 2013.
[10] A. L. Sarode, H. Sandhu, N. Shah, W. Malick, and H. Zia, “Hot melt extrusion (HME) for amorphous solid dispersions: Predictive tools for processing and impact of drug-polymer interactions on supersaturation,” European Journal of Pharmaceutical Sciences, vol. 48, no. 3, pp. 371–384, 2013.
[11] D. S. Schiller and H. B. Fung, “Posaconazole: an extended-spectrum triazole antifungal agent,” Clinical Therapeutics, vol. 29, no. 9, pp. 1862–1886, 2007.
[12] G. Krishna, L. Ma, M. Martinho, R. A. Preston, and E. O’mara, “A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 11, Article ID dks268, pp. 2725–2730, 2012.
[13] T. Vasconcelos, B. Sarmento, and P. Costa, “Solid dispersions as strategy to improve oral bioavailability of poorly water soluble drugs,” Journal of Pharmaceutical Investigation, vol. 44, no. 1, pp. 41–49, 2014.

[14] J. Djuris, I. Nikolakakis, S. Ibric, Z. Djuric, and K. Kachrimanis, “Preparation of carbamazepine-soluplus solid dispersions by hot-melt extrusion, and prediction of drug-polymer miscibility by thermodynamic model fitting,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 84, no. 1, pp. 228–237, 2013.

[15] R. Fule, T. Meer, A. Sav, and P. Amin, “Artemether-Soluplus hot-melt extrudate solid dispersion systems for solubility and dissolution rate enhancement with amorphous state characteristics,” Journal of Pharmaceutics, vol. 1, pp. 1–15, 2013.

[16] C. Vo, C. Park, and B. Lee, “Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 85, pp. 799–813, 2013.

[17] I. Tho, B. Liepold, J. Rosenberg, M. Maegerlein, M. Brandl, and G. Fricker, “Formation of nano/micro-dispersions with improved dissolution properties upon dispersion of ritonavir melt extrudate in aqueous media,” European Journal of Pharmaceutical Sciences, vol. 40, no. 1, pp. 25–32, 2010.

[18] M. Zhang, H. Li, B. Lang et al., “Formulation and delivery of improved amorphous fenofibrate solid dispersions prepared by thin film freezing,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 82, no. 3, pp. 534–544, 2012.

[19] R. Fule, T. Meer, A. Sav, and P. Amin, “Solubility and dissolution rate enhancement of lumezantrine using hot melt extrusion technology with physicochemical characterisation,” Journal of Pharmaceutical Investigation, vol. 43, no. 4, pp. 305–321, 2013.

[20] A. L. Sarode, H. Sandhu, N. Shah, W. Malick, and H. Zia, “Hot melt extrusion (HME) for amorphous solid dispersions: Predictive tools for processing and impact of drug-polymer interactions on supersaturation,” European Journal of Pharmaceutical Sciences, vol. 48, no. 3, pp. 371–384, 2013.

[21] D. S. Schiller and H. B. Fung, “Posaconazole: an extended-spectrum triazole antifungal agent,” Clinical Therapeutics, vol. 29, no. 9, pp. 1862–1886, 2007.

[22] G. Krishna, L. Ma, M. Martinho, R. A. Preston, and E. O’mara, “A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers,” Journal of Antimicrobial Chemotherapy, vol. 67, no. 11, Article ID dks268, pp. 2725–2730, 2012.

[23] T. Vasconcelos, B. Sarmento, and P. Costa, "Solid dispersions as strategy to improve oral bioavailability of poorly water soluble drugs," Journal of Pharmaceutical Investigation, vol. 44, no. 1, pp. 41–49, 2014.
drugs," Drug Discovery Today, vol. 12, no. 23-24, pp. 1068–1075, 2007.

[14] I. M. Kalogeras, "A novel approach for analyzing glass-transition temperature vs. composition patterns: application to pharmaceutical compound + polymer systems," European Journal of Pharmaceutical Sciences, vol. 42, no. 5, pp. 470–483, 2011.

[15] H. Konno and L. S. Taylor, "Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine," Journal of Pharmaceutical Sciences, vol. 95, no. 12, pp. 2692–2705, 2006.

[16] D. J. Greenhalgh, A. C. Williams, P. Timmins, and P. York, "Solubility parameters as predictors of miscibility in solid dispersions," Journal of Pharmaceutical Sciences, vol. 88, no. 11, pp. 1182–1190, 1999.

[17] R. Dukeck, P. Sieger, and P. Karmwar, "Investigation and correlation of physical stability, dissolution behaviour and interaction parameter of amorphous solid dispersions of telmisartan: a drug development perspective," European Journal of Pharmaceutical Sciences, vol. 49, no. 4, pp. 723–731, 2013.

[18] P. J. Marsac, S. L. Shamblin, and L. S. Taylor, "Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility," Pharmaceutical Research, vol. 23, no. 10, pp. 2417–2426, 2006.

[19] G. P. Andrews, O. Abu-Diak, F. Kusmanto, P. Hornsby, Z. Hui, and D. S. Jones, "Physicochemical characterization and drug-release properties of celecoxib hot-melt extruded glass solutions," Journal of Pharmacy and Pharmacology, vol. 62, no. 11, pp. 1580–1590, 2010.

[20] E. Widjaja, P. Kanaujia, G. Lau et al., "Detection of trace crystallinity in an amorphous system using Raman microscopy and chemometric analysis," European Journal of Pharmaceutical Sciences, vol. 42, no. 1-2, pp. 45–54, 2011.

[21] E. Reitz, C. Vervaet, R. H. H. Neubert, and M. Thommes, "Solid crystal suspensions containing griseofulvin—preparation and bioavailability testing," European Journal of Pharmaceutics and Biopharmaceutics, vol. 83, no. 2, pp. 193–202, 2013.

[22] M. Maniruzzaman, D. J. Morgan, A. P. Mendum, J. Pang, M. J. Snowden, and D. Douroumis, "Drug-polymer intermolecular interactions in hot-melt extruded solid dispersions," International Journal of Pharmaceutics, vol. 443, no. 1-2, pp. 199–208, 2013.

[23] M. Macháčková, J. Tokarsky, and P. Capkova, "A simple molecular modeling method for the characterization of polymeric drug carriers," European Journal of Pharmaceutical Sciences, vol. 48, no. 1-2, pp. 316–322, 2013.

[24] P. Zhou, X. Xie, D. P. Knight, X. Zong, F. Deng, and W. Yao, "Effects of pH and calcium ions on the conformational transitions in silk fibroin using 2D Raman correlation spectroscopy and 13C solid-state NMR," Biochemistry, vol. 43, no. 35, pp. 11302–11311, 2004.

[25] C. V. Garcia, G. R. Costa, and A. S. L. Mendez, "Stability-indicating HPLC method for posaconazole bulk assay," Scientia Pharmaceutica, vol. 80, no. 2, pp. 317–327, 2012.

[26] H. Kim, P. Likhari, P. Kumari, C. Lin, and A. A. Nomez, "High-performance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum," Journal of Chromatography B: Biomedical Sciences and Applications, vol. 738, no. 1, pp. 93–98, 2000.

[27] J. Breitenbach, "Melt extrusion: from process to drug delivery technology," European Journal of Pharmaceutics and Biopharmaceutics, vol. 54, no. 2, pp. 107–117, 2002.

[28] I. Weuts, D. Kempen, A. Decorte et al., "Phase behaviour analysis of solid dispersions of loperamide and two structurally related compounds with the polymers PVP-K30 and PVP-VA64," European Journal of Pharmaceutical Sciences, vol. 22, no. 5, pp. 375–385, 2004.

[29] E. Karavas, E. Georgarakis, M. P. Sigalas, K. Avgoustakis, and D. Bikiaris, "Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions," European Journal of Pharmaceutics and Biopharmaceutics, vol. 66, no. 3, pp. 334–347, 2007.

[30] C. Leuner and J. Dressman, "Improving drug solubility for oral delivery using solid dispersions," European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 47–60, 2000.

[31] L. Saerens, L. Dieirickx, B. Lenain, C. Vervaet, J. P. Remon, and T. D. Beer, "Raman spectroscopy for the in-line polymer-drug quantification and solid state characterization during a pharmaceutical hot-melt extrusion process," European Journal of Pharmaceutics and Biopharmaceutics, vol. 77, no. 1, pp. 158–163, 2011.

[32] M. E. Lauer, M. Siam, I. Tardio, S. Page, J. H. Kindt, and O. Grassmann, "Rapid assessment of homogeneity and reliability of amorphous solid dispersions by atomic force microscopy—from Bench to Batch," Pharmaceutical Research, vol. 30, no. 8, pp. 2010–2022, 2013.

[33] A. Almeida, L. Saerens, T. De Beer, J. P. Remon, and C. Vervaet, "Upscaling and in-line process monitoring via spectroscopic techniques of ethylene vinyl acetate hot-melt extruded formulations," International Journal of Pharmaceutics, vol. 439, no. 1-2, pp. 223–229, 2012.

[34] N. Zajc, A. Obreza, M. Bele, and S. Srčič, "Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method," International Journal of Pharmaceutics, vol. 291, no. 1-2, pp. 51–58, 2005.

[35] F. Jiuj, Z. Lili, G. Tingting, T. Xing, and H. Haibing, "Stable nimodipine tablets with high bioavailability containing NM-SD prepared by hot-melt extrusion," Powder Technology, vol. 204, no. 2-3, pp. 214–221, 2010.

[36] G. Krishna, A. Moton, M. Lei, M. M. Medlock, and J. McLeod, "Pharmacokinetics and 694 absorption of posaconazole oral suspension under various gastric conditions in healthy 695 volunteers," Antimicrobial Agents and Chemotherapy, vol. 53, no. 3, pp. 958–966, 2009.

[37] R. Courtney, S. Pai, M. Laughlin, J. Lim, and V. Batra, "Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults," Antimicrobial Agents and Chemotherapy, vol. 47, no. 9, pp. 2788–2795, 2003.

[38] E. S. Dodds Ashley, J. B. Varkey, G. Krishna et al., "Pharmacokinetics of posaconazole administered orally by nasogastric tube in healthy volunteers," Antimicrobial Agents and Chemotherapy, vol. 53, no. 7, pp. 2960–2964, 2009.
